Prospects of 3D Bioprinting as a Possible Treatment for Cancer Cachexia
Mustafa Galib 1, Yusha Araf 2 * , Iftekhar Bin Naser 1, Salman Khan Promon 3 *
More Detail
1 Biotechnology Program, Department of Mathematics and Natural Sciences, BRAC University, Dhaka, Bangladesh2 Department of Genetic Engineering and Biotechnology, School of Life Sciences, Shahjalal University of Science and Technology, Sylhet, Bangladesh3 Department of Life Sciences, School of Environment and Life Sciences, Independent University, Bangladesh (IUB), Bashundhara, Dhaka, Bangladesh* Corresponding Author


Cancer cachexia is a multifactorial syndrome characterized by persistent muscle atrophy, functional impairment, anorexia, weakness, fatigue, anemia, and reduced antitumor treatment tolerance. As a result, the patients’ quality of life suffers. Cachexia is responsible for approximately 22-25 percent of cancer deaths. This article discusses the signs and symptoms of cancer cachexia, as well as the mediators, treatment options, and future prospects for 3D bioprinting. Protein breakdown, inflammatory cytokines activation, and mitochondrial alteration are all factors that contribute to cachexia, according to research. Cachexia has eluded standard treatment despite the use of proper nutrition, physical activity, anti-inflammatory drugs, chemotherapy, and grafting attempts. By attempting to fabricate 3D constructs that mimic native muscle tissues, 3D bioprinting shows a lot of promise when compared to traditional methods. Some 3D bioprinting techniques have been discussed in this review, along with their benefits and drawbacks, as well as their achievements and challenges in in-vivo applications. Muscle atrophy can be repaired with neural integration or muscle-tendon units. However, properly bio-printing these complex muscles remains a challenge. Although new bio-inks or 3D printers can be used to fabricate high-resolution constructs, progress can be made. This review study uses secondary data to show why 3D bioprinting could be a viable alternative to treating cachexia.


This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Review Article

J CLIN EXP INVEST, 2021, Volume 12, Issue 4, Article No: em00783

Publication date: 21 Oct 2021

Article Views: 1069

Article Downloads: 383

Open Access References How to cite this article